As an IL-23 inhibitor, XTS reduces the production of IL-17 factors in synovial tissue by targeting IL-23, thereby regulating the IL-23/IL-17/NF-κB inflammatory axis and alleviating synovial inflammation in RA. This evidence concerns the gene NFKB1 and inflammatory response.